Cardiff Oncology, Inc. Balance Sheet
CRDF|14 years of annual SEC 10-K data (FY2012-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 14 fiscal years. All figures from audited SEC 10-K filings.
Cardiff Oncology, Inc. had $62M in total assets and $45M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $17.5M | $51.5M | $21.7M | $16.3M | $11.9M | $131.0M | $10.2M | $8.2M | $13.9M | $27.3M | $67.5M | $27.3M | $700.4K | $58.7K |
| Accounts Receivable | $182.0K | $773.0K | $288.0K | $771.0K | $535.0K | $320.0K | $203.5K | $167.8K | $77.1K | $100.5K | $98.7K | $56.7K | $79.0K | $168.4K |
| Current Assets | $60.1M | $95.1M | $77.4M | $111.3M | $146.1M | $133.4M | $11.4M | $12.8M | $9.5M | $39.0M | $68.4M | $27.7M | $26.1M | $11.0M |
| PP&E (Net) | $578.0K | $898.0K | $1.2M | $1.3M | $382.0K | $624.0K | $877.8K | $1.3M | $2.4M | $3.8M | $2.7M | $840.4K | $750.6K | $254.7K |
| Total Assets | $61.9M | $97.2M | $81.6M | $116.2M | $149.5M | $134.7M | $13.1M | $14.2M | $12.3M | $44.0M | $71.4M | $28.9M | $27.2M | $11.7M |
| Current Liabilities | $16.4M | $13.4M | $10.4M | $7.8M | $6.6M | $6.1M | $4.8M | $3.0M | $3.9M | $7.8M | $8.2M | $4.5M | $2.0M | $730.4K |
| Shareholders' Equity | $45.4M | $69.7M | $106.3M | $140.4M | $128.2M | $128.2M | $7.3M | $6.5M | $19.8M | $48.7M | $48.7M | $8.3M | -$4.2M | $27.2K |